Characterization of a murine model with arteritis induced by Nod1 ligand, FK565: A comparative study with a CAWS-induced model

References

• Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54(3):271–6.
   PubMed Web of Science ®Google Scholar
• Fukazawa R, Ikegam E, Watanabe M, Hajikano M, Kamisago M, Katsube Y, et al. Coronary artery aneurysm induced by Kawasaki disease in children show features typical senescence. Circ J. 2007;71(5):709–15.
   PubMed Web of Science ®Google Scholar
• Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015;11(8):475–82.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67(14):1738–49.
   PubMed Web of Science ®Google Scholar
• Chen KY, Curtis N, Dahdah N, Kowalski R, Cheung M, Burgner DP. Kawasaki disease and cardiovascular risk: a comprehensive review of subclinical vascular changes in the longer term. Acta Paediatr. 2016;105(7):752–61.
   PubMed Web of Science ®Google Scholar
• Leung DY, Meissner HC, Shulman ST, Mason WH, Gerber MA, Glode MP, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr. 2002;140(6):742–6.
   PubMed Web of Science ®Google Scholar
• Hoang LT, Shimizu C, Ling L, Naim AN, Khor CC, Tremoulet AH, et al. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. Genome Med. 2014;6(11):541.
   PubMed Web of Science ®Google Scholar
• Hara T, Nakashima Y, Sakai Y, Nishio H, Motomura Y, Yamasaki S. Kawasaki disease: a matter of innate immunity. Clin Exp Immunol. 2016;186(2):134–43.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005;47(3):305–10.
   PubMed Web of Science ®Google Scholar
• Ohashi R, Fukazawa R, Watanabe M, Tajima H, Nagi-Miura N, Ohno N, et al. Etanercept suppresses arteritis in a murine model of Kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med. 2013;2013:543141.
   PubMedGoogle Scholar
• Nagi-Miura N, Okuzaki D, Torigata K, Sakurai MA, Ito A, Ohno N, et al. CAWS administration increases the expression of interferon γ and complement factors that lead to severe vasculitis in DBA/2 mice. BMC Immunol. 2013;14:44.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Oharaseki T, Wakayama M, Yokouchi Y, Naoe S, Murata H. Histopathological features of murine systemic vasculitis caused by Candida albicans extract—an animal model of Kawasaki disease. Inflamm Res. 2004;53(2):72–7.
   PubMed Web of Science ®Google Scholar
• Nagi-Miura N, Harada T, Shinohara H, Kurihara K, Adachi Y, Ishida-Okawara A, et al. Lethal and severe coronary arteritis in DBA/2 mice induced by fungal pathogen, CAWS, Candida albicans water-soluble fraction. Atherosclerosis. 2006;186(2):310–20.
   PubMed Web of Science ®Google Scholar
• Oharaseki T, Yokouchi Y, Yamada H, Mamada H, Muto S, Sadamoto K, et al. The role of TNF-α in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide. Mod Rheumatol. 2014;24(1):120–8.
   PubMed Web of Science ®Google Scholar
• Geddes K, Magalhães JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 2009;8(6):465–79.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Ryffel B, Quesniaux VF, Cartwright N, Paul-Clark M. Role of pattern-recognition receptors in cardiovascular health and disease. Biochem Soc Trans. 2007;35(Pt 6):1449–52.
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jéhanno M, Viala J, et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science. 2003;300(5625):1584–7.
   PubMed Web of Science ®Google Scholar
• Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem. 1999;274(21):14560–7.
   PubMed Web of Science ®Google Scholar
• Bertin J, Nir WJ, Fischer CM, Tayber OV, Errada PR, Grant JR, et al. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. J Biol Chem. 1999;274(19):12955–8.
   PubMed Web of Science ®Google Scholar
• Nishio H, Kanno S, Onoyama S, Ikeda K, Tanaka T, Kusuhara K, et al. Nod1 ligands induce site-specific vascular inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):1093–9.
   PubMed Web of Science ®Google Scholar
• Uchiyama M, Ohno N, Miura NN, Adachi Y, Aizawa MW, Tamura H, et al. Chemical and immunochemical characterization of limulus factor G-activating substance of Candida spp. FEMS Immunol Med Microbiol. 1999;24(4):411–20.
   PubMedGoogle Scholar
• Onouchi Z, Ikuta K, Nagamatsu K, Tamiya H, Sakakibara Y, Ando M. Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbits. An experimental model for Kawasaki disease in humans. Angiology. 1995;46(8):679–87.
   PubMed Web of Science ®Google Scholar
• Orenstein JM, Rowley AH. An evaluation of the validity of the animal models of Kawasaki disease vasculopathy. Ultrastruct Pathol. 2014;38(4):245–7.
   PubMed Web of Science ®Google Scholar
• Rosenkranz ME, Schulte DJ, Agle LM, Wong MH, Zhang W, Ivashkiv L, et al. TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation. 2005;112(19):2966–73.
   PubMed Web of Science ®Google Scholar
• Lau AC, Duong TT, Ito S, Yeung RS. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum. 2008;58(3):854–63.
   PubMed Web of Science ®Google Scholar
• Daniels LB, Gordon JB, Burns JC. Kawasaki disease: late cardiovascular sequelae. Curr Opin Cardiol. 2012;27(6):572–7.
   PubMed Web of Science ®Google Scholar
• Lang BA, Silverman ED, Laxer RM, Lau AS. Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr. 1989;115(6):939–43.
   PubMed Web of Science ®Google Scholar
• Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr. 1994;124(5 Pt 1):721–5.
   PubMed Web of Science ®Google Scholar
• Eberhard BA, Andersson U, Laxer RM, Rose V, Silverman ED. Evaluation of the cytokine response in Kawasaki disease. Pediatr Infect Dis J. 1995;14(3):199–203.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141(3):381–7.
   PubMed Web of Science ®Google Scholar
• Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol. 2001;21(3):193–9.
   PubMed Web of Science ®Google Scholar
• Kim DS, Lee HK, Noh GW, Lee SI, Lee KY. Increased serum interleukin-10 level in Kawasaki disease. Yonsei Med J. 1996;37(2):125–30.
   PubMedGoogle Scholar
• Jibiki T, Terai M, Kohno Y. High concentrations of interleukin-8 and monocyte chemoattractant protein-1 in urine of patients with acute Kawasaki disease. Eur J Pediatr. 2004;163(12):749–50.
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol. 2012;13(4):333–42.
   PubMed Web of Science ®Google Scholar
• Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med. 1988;319(25):1670–1.
   PubMed Web of Science ®Google Scholar
• Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125(12):1542–50.
   PubMed Web of Science ®Google Scholar
• Ross R, Agius L. The process of atherogenesis-cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35(Suppl2):S34–S40.
   Web of Science ®Google Scholar
• Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105(10):1158–61.
   PubMed Web of Science ®Google Scholar
• Gibson FC, Hong C, Chou HH, Yumoto H, Chen J, Lien E, et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;109(22):2801–6.
   PubMed Web of Science ®Google Scholar
• Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005;115(11):3149–56.
   PubMed Web of Science ®Google Scholar
• Johansson ME, Zhang XY, Edfeldt K, Lundberg AM, Levin MC, Borén J, et al. Innate immune receptor NOD2 promotes vascular inflammation and formation of lipid-rich necrotic cores in hypercholesterolemic mice. Eur J Immunol. 2014;44(10):3081–92.
   PubMed Web of Science ®Google Scholar
• Kanno S, Nishio H, Tanaka T, Motomura Y, Murata K, Ihara K, et al. Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe−/− mice. J Immunol. 2015;194(2):773–80.
   PubMed Web of Science ®Google Scholar